{"id":29,"date":"2022-02-08T14:10:26","date_gmt":"2022-02-08T13:10:26","guid":{"rendered":"https:\/\/www.icta.fr\/?page_id=29"},"modified":"2023-07-06T15:21:03","modified_gmt":"2023-07-06T13:21:03","slug":"plan-du-site","status":"publish","type":"page","link":"https:\/\/www.icta.fr\/fr\/plan-du-site\/","title":{"rendered":"Plan du site"},"content":{"rendered":"\n<section class=\"wp-block-uagb-section uagb-section__wrap uagb-section__background-undefined uagb-block-4daea6da\"><div class=\"uagb-section__overlay\"><\/div><div class=\"uagb-section__inner-wrap\"><div id=\"wp-realtime-sitemap-pages\"><h3>Pages<\/h3><ul><li class=\"page_item page-item-778\"><a href=\"https:\/\/www.icta.fr\/fr\/etudes-de-cas\/\">Etudes de cas<\/a><\/li>\n<li class=\"page_item page-item-570\"><a href=\"https:\/\/www.icta.fr\/fr\/ou-nous-rencontrer\/\">O\u00f9 nous rencontrer<\/a><\/li>\n<li class=\"page_item page-item-807\"><a href=\"https:\/\/www.icta.fr\/fr\/actualites\/\">Actualit\u00e9s<\/a><\/li>\n<li class=\"page_item page-item-802\"><a href=\"https:\/\/www.icta.fr\/fr\/couverture-internationale\/\">Couverture internationale<\/a><\/li>\n<li class=\"page_item page-item-3\"><a href=\"https:\/\/www.icta.fr\/fr\/politique-de-confidentialite\/\">Politique de confidentialit\u00e9<\/a><\/li>\n<li class=\"page_item page-item-29\"><a href=\"https:\/\/www.icta.fr\/fr\/plan-du-site\/\">Plan du site<\/a><\/li>\n<li class=\"page_item page-item-27\"><a href=\"https:\/\/www.icta.fr\/fr\/mentions-legales\/\">Mentions l\u00e9gales<\/a><\/li>\n<li class=\"page_item page-item-48\"><a href=\"https:\/\/www.icta.fr\/fr\/nous-contacter\/\">Nous contacter<\/a><\/li>\n<li class=\"page_item page-item-601\"><a href=\"https:\/\/www.icta.fr\/fr\/espace-carriere\/\">Espace carri\u00e8re<\/a><\/li>\n<li class=\"page_item page-item-1283\"><a href=\"https:\/\/www.icta.fr\/fr\/message-du-president\/\">Message du Pr\u00e9sident<\/a><\/li>\n<li class=\"page_item page-item-1292\"><a href=\"https:\/\/www.icta.fr\/fr\/plateforme-collaborative-securisee\/\">Plateforme collaborative s\u00e9curis\u00e9e<\/a><\/li>\n<li class=\"page_item page-item-1294\"><a href=\"https:\/\/www.icta.fr\/fr\/outils-informatiques\/\">Outils informatiques<\/a><\/li>\n<li class=\"page_item page-item-158\"><a href=\"https:\/\/www.icta.fr\/fr\/aires-therapeutiques\/\">Aires th\u00e9rapeutiques<\/a><\/li>\n<li class=\"page_item page-item-156\"><a href=\"https:\/\/www.icta.fr\/fr\/expertises\/\">Domaines d&#8217;expertise<\/a><\/li>\n<li class=\"page_item page-item-154\"><a href=\"https:\/\/www.icta.fr\/fr\/services\/\">Services<\/a><\/li>\n<li class=\"page_item page-item-56\"><a href=\"https:\/\/www.icta.fr\/fr\/\">Accueil<\/a><\/li>\n<li class=\"page_item page-item-1287\"><a href=\"https:\/\/www.icta.fr\/fr\/lequipe-icta\/\">L&#8217;\u00e9quipe ICTA<\/a><\/li>\n<li class=\"page_item page-item-1285\"><a href=\"https:\/\/www.icta.fr\/fr\/pourquoi-choisir-icta\/\">Pourquoi choisir ICTA?<\/a><\/li>\n<li class=\"page_item page-item-1243\"><a href=\"https:\/\/www.icta.fr\/fr\/localisation\/\">Localisation<\/a><\/li>\n<li class=\"page_item page-item-1238\"><a href=\"https:\/\/www.icta.fr\/fr\/politique-rse\/\">Politique RSE<\/a><\/li>\n<li class=\"page_item page-item-669\"><a href=\"https:\/\/www.icta.fr\/fr\/publications\/\">Publications<\/a><\/li>\n<\/ul><\/div><div id=\"wp-realtime-sitemap-posts\"><h3>Articles<\/h3><ul><li><a href=\"https:\/\/www.icta.fr\/fr\/journee-de-la-recherche-clinique\/\" title=\"Permalink to Journ\u00e9e de la Recherche Clinique\" rel=\"bookmark\">Journ\u00e9e de la Recherche Clinique<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/icta-iso-27001\/\" title=\"Permalink to ICTA obtient la certification\u00a0ISO 27001\" rel=\"bookmark\">ICTA obtient la certification\u00a0ISO 27001<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/les-journees-icta\/\" title=\"Permalink to Les journ\u00e9es ICTA\" rel=\"bookmark\">Les journ\u00e9es ICTA<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/hasard-et-verite-des-presocratiques-aux-probabilites-frequentistes-ou-bayesiennes\/\" title=\"Permalink to HASARD ET V\u00c9RIT\u00c9 &#8211; Des pr\u00e9socratiques aux probabilit\u00e9s fr\u00e9quentistes ou bay\u00e9siennes\" rel=\"bookmark\">HASARD ET V\u00c9RIT\u00c9 &#8211; Des pr\u00e9socratiques aux probabilit\u00e9s fr\u00e9quentistes ou bay\u00e9siennes<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/icta-resistance-antimicrobriens\/\" title=\"Permalink to ICTA engag\u00e9 dans la r\u00e9sistance aux antimicrobiens via la plateforme S.O.L.V.E &#8211; AMR\" rel=\"bookmark\">ICTA engag\u00e9 dans la r\u00e9sistance aux antimicrobiens via la plateforme S.O.L.V.E &#8211; AMR<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/icta-dmb-ia\/\" title=\"Permalink to Retrouvez nos experts IA \u00e0 la prochaine conf\u00e9rence Data Management Biom\u00e9dical\" rel=\"bookmark\">Retrouvez nos experts IA \u00e0 la prochaine conf\u00e9rence Data Management Biom\u00e9dical<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/dispositif-medical\/\" title=\"Permalink to Le dispositif m\u00e9dical au coeur de notre m\u00e9tier\" rel=\"bookmark\">Le dispositif m\u00e9dical au coeur de notre m\u00e9tier<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/rse\/\" title=\"Permalink to ICTA renouvelle sa m\u00e9daille d&#8217;argent pour ses performances en mati\u00e8re de RSE\" rel=\"bookmark\">ICTA renouvelle sa m\u00e9daille d&#8217;argent pour ses performances en mati\u00e8re de RSE<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/annee-2024\/\" title=\"Permalink to ICTA vous souhaite une ann\u00e9e 2024 prometteuse et prosp\u00e8re\" rel=\"bookmark\">ICTA vous souhaite une ann\u00e9e 2024 prometteuse et prosp\u00e8re<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/icta-reference-nationale-recherche-clinique\/\" title=\"Permalink to La soci\u00e9t\u00e9 dijonnaise ICTA s&#8217;affirme comme r\u00e9f\u00e9rence nationale de la recherche clinique\" rel=\"bookmark\">La soci\u00e9t\u00e9 dijonnaise ICTA s&#8217;affirme comme r\u00e9f\u00e9rence nationale de la recherche clinique<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/journee-de-la-recherche-clinique-icta-animera-pour-le-compte-de-lafcros-la-table-ronde-1-dediee-aux-enjeux-financiers-et-strategiques-des-biotechs-et-medtechs\/\" title=\"Permalink to 12\u00e8me Journ\u00e9e de la Recherche Clinique &#8211; ICTA animera une table ronde 1 d\u00e9di\u00e9e aux enjeux financiers et strat\u00e9giques des biotechs et medtechs\" rel=\"bookmark\">12\u00e8me Journ\u00e9e de la Recherche Clinique &#8211; ICTA animera une table ronde 1 d\u00e9di\u00e9e aux enjeux financiers et strat\u00e9giques des biotechs et medtechs<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/vous-souhaitez-en-savoir-plus-sur-le-developpement-clinique-des-biomedicaments\/\" title=\"Permalink to Vous souhaitez en savoir plus sur le d\u00e9veloppement clinique des biom\u00e9dicaments ?\" rel=\"bookmark\">Vous souhaitez en savoir plus sur le d\u00e9veloppement clinique des biom\u00e9dicaments ?<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/rechercheclinique\/\" title=\"Permalink to Donn\u00e9es cliniques et dispositifs m\u00e9dicaux: qu&#8217;en disent les industriels?\" rel=\"bookmark\">Donn\u00e9es cliniques et dispositifs m\u00e9dicaux: qu&#8217;en disent les industriels?<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/icta-celebre-40-ans-de-croissance-continue\/\" title=\"Permalink to ICTA CELEBRE 40 ANNEES DE CROISSANCE CONTINUE ET SUCCES DEPUIS SES DEBUTS PRECURSEURS EN 1984!\" rel=\"bookmark\">ICTA CELEBRE 40 ANNEES DE CROISSANCE CONTINUE ET SUCCES DEPUIS SES DEBUTS PRECURSEURS EN 1984!<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/les-recentes-icta-iberian-days-ont-marque-une-etape-importante-dans-le-developpement-de-loffre-icta-et-de-son-reseau-de-freelancers-freecra-pour-la-peninsule-iberique\/\" title=\"Permalink to Les r\u00e9centes ICTA Iberian Days ont marqu\u00e9 une \u00e9tape importante dans le d\u00e9veloppement de l&#8217;offre ICTA et de son r\u00e9seau de freelancers \u00abFreeCRA\u00bb pour la p\u00e9ninsule ib\u00e9rique.\" rel=\"bookmark\">Les r\u00e9centes ICTA Iberian Days ont marqu\u00e9 une \u00e9tape importante dans le d\u00e9veloppement de l&#8217;offre ICTA et de son r\u00e9seau de freelancers \u00abFreeCRA\u00bb pour la p\u00e9ninsule ib\u00e9rique.<\/a><\/li><\/ul><\/div><div id=\"wp-realtime-sitemap-domaineexpertises\"><h3>Expertises<\/h3><ul><li><a href=\"https:\/\/www.icta.fr\/fr\/expertises\/developpement-clinique\/\" title=\"Permalink to D\u00e9veloppement clinique\" rel=\"bookmark\">D\u00e9veloppement clinique<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/expertises\/acces-precoce\/\" title=\"Permalink to Acc\u00e8s pr\u00e9coce\" rel=\"bookmark\">Acc\u00e8s pr\u00e9coce<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/expertises\/etudes-en-vie-reelle\/\" title=\"Permalink to \u00c9tudes en vie r\u00e9elle\" rel=\"bookmark\">\u00c9tudes en vie r\u00e9elle<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/expertises\/analyse-donnees-de-sante\/\" title=\"Permalink to Analyse des donn\u00e9es de sant\u00e9\" rel=\"bookmark\">Analyse des donn\u00e9es de sant\u00e9<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/expertises\/biotechnologie\/\" title=\"Permalink to Biotechnologie\" rel=\"bookmark\">Biotechnologie<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/expertises\/dispositif-medical\/\" title=\"Permalink to Dispositif m\u00e9dical\" rel=\"bookmark\">Dispositif m\u00e9dical<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/expertises\/etudes-decentralisees\/\" title=\"Permalink to \u00c9tudes d\u00e9centralis\u00e9es\" rel=\"bookmark\">\u00c9tudes d\u00e9centralis\u00e9es<\/a><\/li><\/ul><\/div><div id=\"wp-realtime-sitemap-services\"><h3>Services<\/h3><ul><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/conception\/\" title=\"Permalink to Conception\" rel=\"bookmark\">Conception<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/affaires-reglementaires\/\" title=\"Permalink to Affaires r\u00e9glementaires\" rel=\"bookmark\">Affaires r\u00e9glementaires<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/gestion-de-projet\/\" title=\"Permalink to Gestion de projet\" rel=\"bookmark\">Gestion de projet<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/mise-a-disposition-de-personnel\/\" title=\"Permalink to Mise \u00e0 disposition de personnel\" rel=\"bookmark\">Mise \u00e0 disposition de personnel<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/sourcing-decra-freelancers\/\" title=\"Permalink to Sourcing de CRA freelancers\" rel=\"bookmark\">Sourcing de CRA freelancers<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/approche-risk-based-monitoring\/\" title=\"Permalink to Risk-based monitoring\" rel=\"bookmark\">Risk-based monitoring<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/vigilance\/\" title=\"Permalink to Vigilance\" rel=\"bookmark\">Vigilance<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/data-management\/\" title=\"Permalink to Data management\" rel=\"bookmark\">Data management<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/biostatistiques\/\" title=\"Permalink to Biostatistiques\" rel=\"bookmark\">Biostatistiques<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/services\/redaction-medicale\/\" title=\"Permalink to R\u00e9daction m\u00e9dicale\" rel=\"bookmark\">R\u00e9daction m\u00e9dicale<\/a><\/li><\/ul><\/div><div id=\"wp-realtime-sitemap-emplois\"><h3>Emplois<\/h3><ul><li><a href=\"https:\/\/www.icta.fr\/fr\/emplois\/assistante-de-direction-et-juridique-bilingue-h-f\/\" title=\"Permalink to Assistant(e) de Direction et Juridique Bilingue  H\/F\" rel=\"bookmark\">Assistant(e) de Direction et Juridique Bilingue  H\/F<\/a><\/li><\/ul><\/div><div id=\"wp-realtime-sitemap-casclients\"><h3>Cas clients<\/h3><ul><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/prevention-treatment-of-a-non-serious-dermatological-condition-on-the-foot\/\" title=\"Permalink to Prevention &amp; Treatment of a non-serious dermatological condition on the foot\" rel=\"bookmark\">Prevention &amp; Treatment of a non-serious dermatological condition on the foot<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/long-term-safety-evaluation-of-a-medicinal-product-in-inherited-haematological-disorder-in-europe\/\" title=\"Permalink to Long-Term Safety Evaluation of a Medicinal Product in Inherited Haematological Disorder in Europe\" rel=\"bookmark\">Long-Term Safety Evaluation of a Medicinal Product in Inherited Haematological Disorder in Europe<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/a-phase-1-2-open-label-safety-tolerability-and-preliminary-efficacy-study-of-implantation-into-one-eye-of-an-atmp-in-patients-with-retinitis-pigmentosa-due-to-monogenic-mutation\/\" title=\"Permalink to A phase 1\/2, open-label, safety, tolerability and preliminary efficacy study of implantation into one eye of an ATMP in patients with retinitis pigmentosa due to monogenic mutation\" rel=\"bookmark\">A phase 1\/2, open-label, safety, tolerability and preliminary efficacy study of implantation into one eye of an ATMP in patients with retinitis pigmentosa due to monogenic mutation<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/derived-cell-atmp-implantation-for-the-treatment-of-fecal-incontinence-a-multicentre-randomized-double-blind-placebo-controlled-parallel-group-dose-finding-clinical-study\/\" title=\"Permalink to Derived cell ATMP implantation for the treatment of fecal incontinence: a multicentre, randomized, double-blind, placebo-controlled, parallel-group, dose-finding clinical study.\" rel=\"bookmark\">Derived cell ATMP implantation for the treatment of fecal incontinence: a multicentre, randomized, double-blind, placebo-controlled, parallel-group, dose-finding clinical study.<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/open-non-controlled-parallel-cohorts-multicenter-phase-2a-trial-for-the-evaluation-of-the-antitumor-activity-of-an-imp-single-agent-and-in-combination-with-chemotherapy-in-patients-with-locally-ad\/\" title=\"Permalink to Open, non-controlled, parallel cohorts, multicenter, phase 2a trial for the evaluation of the antitumor activity of an IMP single agent and in combination with chemotherapy in patients with locally advanced or metastatic colorectal cancer.\" rel=\"bookmark\">Open, non-controlled, parallel cohorts, multicenter, phase 2a trial for the evaluation of the antitumor activity of an IMP single agent and in combination with chemotherapy in patients with locally advanced or metastatic colorectal cancer.<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/pain-relief-and-protection-of-three-self-treated-dermatological-foot-conditions\/\" title=\"Permalink to Pain relief and protection of three self-treated dermatological foot conditions\" rel=\"bookmark\">Pain relief and protection of three self-treated dermatological foot conditions<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/a-prospective-study-on-an-imp-pet-ct-imaging-in-biochemical-recurrence-of-prostate-cancer\/\" title=\"Permalink to A Prospective study on an IMP PET\/CT Imaging in Biochemical Recurrence of Prostate Cancer\" rel=\"bookmark\">A Prospective study on an IMP PET\/CT Imaging in Biochemical Recurrence of Prostate Cancer<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/lung-cancer-patients-treated-with-a-new-pd-1-imp-a-longitudinal-prospective-observational-multicentric-study-in-france\/\" title=\"Permalink to Lung cancer patients treated with a new PD-1 IMP: A longitudinal, prospective, observational, multicentric study in France\" rel=\"bookmark\">Lung cancer patients treated with a new PD-1 IMP: A longitudinal, prospective, observational, multicentric study in France<\/a><\/li><li><a href=\"https:\/\/www.icta.fr\/fr\/cas-clients\/a-first-in-human-trial-of-monoclonal-antibody-imp-in-patients-with-anti-mullerian-hormone-receptor-ii-amhrii-positive-gynecological-cancers\/\" title=\"Permalink to A First-In-Human trial of monoclonal antibody IMP in patients with Anti-M\u00fcllerian-Hormone-Receptor II (AMHRII) positive gynecological cancers\" rel=\"bookmark\">A First-In-Human trial of monoclonal antibody IMP in patients with Anti-M\u00fcllerian-Hormone-Receptor II (AMHRII) positive gynecological cancers<\/a><\/li><\/ul><\/div>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":3732,"parent":0,"menu_order":11,"comment_status":"closed","ping_status":"closed","template":"typewhite.php","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","inline_featured_image":false,"_uag_custom_page_level_css":"","kk_blocks_editor_width":"","_kiokenblocks_attr":"","_kiokenblocks_dimensions":"","footnotes":""},"class_list":["post-29","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"uagb_featured_image_src":{"full":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1.png",2732,324,false],"thumbnail":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-128x88.png",128,88,true],"medium":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-300x36.png",300,36,true],"medium_large":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-768x91.png",768,91,true],"large":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-1024x121.png",1024,121,true],"1536x1536":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-1536x182.png",1536,182,true],"2048x2048":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-2048x243.png",2048,243,true],"post-thumbnail":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-1568x186.png",1568,186,true],"wpm_taille_1":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-364x257.png",364,257,true],"wpm_taille_slider":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1-240x145.png",240,145,true],"gform-image-choice-sm":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1.png",300,36,false],"gform-image-choice-md":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1.png",400,47,false],"gform-image-choice-lg":["https:\/\/www.icta.fr\/wp-content\/uploads\/bandeau-icta-1.png",600,71,false]},"uagb_author_info":{"display_name":"ictvsi6372","author_link":"https:\/\/www.icta.fr\/fr\/author\/jhvision-icta\/"},"uagb_comment_info":0,"uagb_excerpt":null,"_links":{"self":[{"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/pages\/29","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/comments?post=29"}],"version-history":[{"count":7,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/pages\/29\/revisions"}],"predecessor-version":[{"id":8817,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/pages\/29\/revisions\/8817"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/media\/3732"}],"wp:attachment":[{"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/media?parent=29"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}